In Figure 3E of the original article, the authors showed a western blot of different Ba/F3 cell lines expressing various HER2 exon 20 mutations. It was recently brought to the authors’ attention that there was an extra lane on the western blot and that the labels on the blot were unclearly labeled. The unintentional error was that the last lane of the western blot for HER2 (top row) contained a positive control cell line, H1781, with known expression of HER2 that was not cropped from the image, and the labels were shifted incorrectly. This error has now been corrected in the article online. While this correction does not affect the findings or the conclusions of the study, the authors would like to apologize for this error and any confusion that it may have caused for readers.
. Author manuscript; available in PMC: 2020 May 22.
Published in final edited form as: Cancer Cell. 2020 Mar 16;37(3):420. doi: 10.1016/j.ccell.2020.03.003
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P Robichaux
, Yasir Y Elamin
, RSK Vijayan
, Monique B Nilsson
, Lemei Hu
, Junqin He
, Fahao Zhang
, Marlese Pisegna
, Alissa Poteete
, Huiying Sun
, Shuai Li
, Ting Chen
, Han Han
, Marcelo Vailati Negrao
, Jordi Rodon Ahnert
, Lixia Diao
, Jing Wang
, Xiuning Le
, Funda Meric-Bernstam
, Mark Routbort
, Brent Roeck
, Zane Yang
, Victoria M Raymond
, Richard B Lanman
, Garrett M Frampton
, Vincent A Miller
, Alexa B Schrock
, Lee A Albacker
, Kwok-kin Wong
, Jason B Cross
, John V Heymach
*
Jacqulyne P Robichaux
Find articles by Jacqulyne P Robichaux
Yasir Y Elamin
Find articles by Yasir Y Elamin
RSK Vijayan
Find articles by RSK Vijayan
Monique B Nilsson
Find articles by Monique B Nilsson
Lemei Hu
Find articles by Lemei Hu
Junqin He
Find articles by Junqin He
Fahao Zhang
Find articles by Fahao Zhang
Marlese Pisegna
Find articles by Marlese Pisegna
Alissa Poteete
Find articles by Alissa Poteete
Huiying Sun
Find articles by Huiying Sun
Shuai Li
Find articles by Shuai Li
Ting Chen
Find articles by Ting Chen
Han Han
Find articles by Han Han
Marcelo Vailati Negrao
Find articles by Marcelo Vailati Negrao
Jordi Rodon Ahnert
Find articles by Jordi Rodon Ahnert
Lixia Diao
Find articles by Lixia Diao
Jing Wang
Find articles by Jing Wang
Xiuning Le
Find articles by Xiuning Le
Funda Meric-Bernstam
Find articles by Funda Meric-Bernstam
Mark Routbort
Find articles by Mark Routbort
Brent Roeck
Find articles by Brent Roeck
Zane Yang
Find articles by Zane Yang
Victoria M Raymond
Find articles by Victoria M Raymond
Richard B Lanman
Find articles by Richard B Lanman
Garrett M Frampton
Find articles by Garrett M Frampton
Vincent A Miller
Find articles by Vincent A Miller
Alexa B Schrock
Find articles by Alexa B Schrock
Lee A Albacker
Find articles by Lee A Albacker
Kwok-kin Wong
Find articles by Kwok-kin Wong
Jason B Cross
Find articles by Jason B Cross
John V Heymach
Find articles by John V Heymach
*
Correspondence: jheymach@mdanderson.org
PMCID: PMC7241090 NIHMSID: NIHMS1579511 PMID: 32183953
The publisher's version of this article is available at Cancer Cell
This corrects the article "Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity" in volume 36 on page 444.